Form 4: Oncocyte Corp Executive James Yang Liu Reports Stock Option Grant
SEC Form 4 Filing
James Yang Liu, a Senior Director at Oncocyte Corp, reports the acquisition of stock options.
Summary
- On May 20, 2024, James Yang Liu, a Senior Director at Oncocyte Corp, reported a transaction related to derivative securities.
- Liu acquired options to purchase 10,000 shares of Oncocyte Corp common stock at an exercise price of $2.76.
- These options vest over a period of 4 years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, and does not contain any information that would significantly impact sentiment.
Positives
- The grant of stock options to a senior director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of the stock option grant. |
| 05/22/2024 | Date of signature on the Form 4 filing. |
| 05/20/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.